Resveratrol as a therapeutic agent for alzheimer's disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Ma, Teng ^a   Tan, Meng Shan ^b   Yu, Jin Tai ^a,b   Tan, Lan ^a,b  

^a QINGDAO UNIVERSITY   (China)

^b OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; RESVERATROL; TAU PROTEIN; ANTIOXIDANT; NEUROPROTECTIVE AGENT; STILBENE DERIVATIVE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CELL CULTURE; CLINICAL RESEARCH; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; STILBENES;

EID: 84915820956     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/350516     Document Type: Article

References (97)

1. Selkoe D. J., Alzheimer's disease: genes, proteins, and therapy. Physiological Reviews 2001 81 2 741 766 2-s2.0-0035066332
2. Granzotto A., Zatta P., Resveratrol acts not through Anti-Aggregative pathways but mainly via its scavenging properties against A β and A β -metal complexes toxicity. PLoS ONE 2011 6 6 e21565 10.1371/journal.pone.0021565 2-s2.0-79959606870
3. Yaffe K., Treatment of Alzheimer disease and prognosis of dementia: time to translate research to results. JAMA-Journal of the American Medical Association 2010 304 17 1952 1953 10.1001/jama.2010.1625 2-s2.0-78049360032
4. Allain H., Bentué-Ferrer D., Tribut O., Gauthier S., Michel B.-F., Rochelle C. D.-L., Alzheimer's disease: the pharmacological pathway. Fundamental and Clinical Pharmacology 2003 17 4 419 428 10.1046/j.1472-8206.2003.00153.x 2-s2.0-0041668189
5. Kim J., Lee H. J., Lee K. W., Naturally occurring phytochemicals for the prevention of Alzheimer's disease. Journal of Neurochemistry 2010 112 6 1415 1430 10.1111/j.1471-4159.2009.06562.x 2-s2.0-77349084360
6. Li F., Gong Q., Dong H., Shi J., Resveratrol, a neuroprotective supplement for Alzheimer's disease. Current Pharmaceutical Design 2012 18 1 27 33 10.2174/138161212798919075 2-s2.0-84855853383
7. Ferrières J., The French paradox: lessons for other countries. Heart 2004 90 1 107 111 10.1136/heart.90.1.107 2-s2.0-0346059361
8. Baur J. A., Sinclair D. A., Therapeutic potential of resveratrol: the in vivo evidence. Nature Reviews Drug Discovery 2006 5 6 493 506 10.1038/nrd2060 2-s2.0-33745962138
9. Saiko P., Szakmary A., Jaeger W., Szekeres T., Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutation Research-Reviews in Mutation Research 2008 658 1-2 68 94 10.1016/j.mrrev.2007.08.004 2-s2.0-38649132291
10. Oomen C. A., Farkas E., Roman V., van der Beek E. M., Luiten P. G. M., Meerlo P., Resveratrol preserves cerebrovascular density and cognitive function in aging mice. Frontiers in Aging Neuroscience 2009 1 4 10.3389/neuro.24.004.2009 2-s2.0-79960215837
11. Perl D. P., Neuropathology of Alzheimer's disease. Mount Sinai Journal of Medicine 2010 77 1 32 42 10.1002/msj.20157 2-s2.0-75649135280
12. Hardy J., Alzheimer's disease: the amyloid cascade hypothesis-an update and reappraisal. Journal of Alzheimer's Disease 2006 9 3 supplement 151 153 2-s2.0-33747447506
13. Roberson E. D., Mucke L., 100 Years and counting: prospects for defeating Alzheimer's disease. Science 2006 314 5800 781 784 10.1126/science.1132813 2-s2.0-33750731675
14. Nunomura A., Oxidative stress hypothesis for Alzheimer's disease and its potential therapeutic implications. Rinsho Shinkeigaku 2013 53 11 1043 1045 10.5692/clinicalneurol.53.1043 2-s2.0-84891767976
15. Abolfathi A. A., Mohajeri D., Rezaie A., Nazeri M., Protective effects of green tea extract against hepatic tissue injury in streptozotocin-induced diabetic rats. Evidence-based Complementary and Alternative Medicine 2012 2012 10 740671 10.1155/2012/740671 2-s2.0-84858198745
16. Heneka M. T., O'Banion M. K., Inflammatory processes in Alzheimer's disease. Journal of Neuroimmunology 2007 184 1-2 69 91 10.1016/j.jneuroim.2006.11.017 2-s2.0-33847613885
17. Capiralla H., Vingtdeux V., Zhao H., Sankowski R., Al-Abed Y., Davies P., Marambaud P., Resveratrol mitigates lipopolysaccharide- and A β -mediated microglial inflammation by inhibiting the TLR4/NF- B/STAT signaling cascade. Journal of Neurochemistry 2012 120 3 461 472 10.1111/j.1471-4159.2011.07594.x 2-s2.0-84855686976
18. 2 caspase-3, NF- B, p53 and c-Jun. NeuroToxicology 2002 23 3 351 365 10.1016/S0161-813X(02)00081-5 2-s2.0-0036728812
19. Tansey M. G., McCoy M. K., Frank-Cannon T. C., Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Experimental Neurology 2007 208 1 1 25 10.1016/j.expneurol.2007.07.004 2-s2.0-35348966882
20. Liu Y., Qin L., Wilson B. C., An L., Hong J.-S., Liu B., Inhibition by naloxone stereoisomers of β -amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. Journal of Pharmacology and Experimental Therapeutics 2002 302 3 1212 1219 10.1124/jpet.102.035956 2-s2.0-0036721255
21. Villaflores O. B., Chen Y.-J., Chen C.-P., Yeh J.-M., Wu T.-Y., Curcuminoids and resveratrol as anti-Alzheimer agents. Taiwanese Journal of Obstetrics and Gynecology 2012 51 4 515 525 10.1016/j.tjog.2012.09.005 2-s2.0-84871717940
22. del C. Alonso A., Zaidi T., Novak M., Grundke-Iqbal I., Iqbal K., Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments. Proceedings of the National Academy of Sciences of the United States of America 2001 98 12 6923 6928 10.1073/pnas.121119298 2-s2.0-0035811050
23. Alonso A. D. C., Li B., Grundke-Iqbal I., Iqbal K., Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Current Alzheimer Research 2008 5 4 375 384 10.2174/156720508785132307 2-s2.0-48749090279
24. Iqbal K., Liu F., Gong C.-X., Grundke-Iqbal I., Tau in Alzheimer disease and related tauopathies. Current Alzheimer research 2010 7 8 656 664 10.2174/156720510793611592 2-s2.0-84862833600
25. Wilcock D. M., Gharkholonarehe N., van Nostrand W. E., Davis J., Vitek M. P., Colton C. A., Amyloid reduction by amyloid- β vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. Journal of Neuroscience 2009 29 25 7957 7965 10.1523/JNEUROSCI.1339-09.2009 2-s2.0-67649363905
26. Holtzman D. M., Alzheimer's disease: moving towards a vaccine. Nature 2008 454 7203 418 420 10.1038/454418a 2-s2.0-47949102462
27. Mallucci G. R., White M. D., Farmer M., Dickinson A., Khatun H., Powell A. D., Brandner S., Jefferys J. G., Collinge J., Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 2007 53 3 325 335 10.1016/j.neuron.2007.01.005 2-s2.0-33846538022
28. Selkoe D. J., Alzheimer's disease is a synaptic failure. Science 2002 298 5594 789 791 10.1126/science.1074069 2-s2.0-0037174618
29. Pasinetti G. M., Wang J., Marambaud P., Ferruzzi M., Gregor P., Knable L. A., Ho L., Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders. Experimental Neurology 2011 232 1 1 6 10.1016/j.expneurol.2011.08.014 2-s2.0-80053937926
30. Wang J., Ho L., Zhao Z., Seror I., Humala N., Dickstein D. L., Thiyagarajan M., Percival S. S., Talcott S. T., Pasinetti G. M., Moderate consumption of Cabernet Sauvignon attenuates A β neuropathology in a mouse model of Alzheimer's disease. The FASEB Journal 2006 20 13 2313 2320 10.1096/fj.06-6281com 2-s2.0-33845620279
31. Cleary J. P., Walsh D. M., Hofmeister J. J., Shankar G. M., Kuskowski M. A., Selkoe D. J., Ashe K. H., Natural oligomers of the amyloid- β protein specifically disrupt cognitive function. Nature Neuroscience 2005 8 1 79 84 10.1038/nn1372 2-s2.0-16644379264
32. Wang J., Ho L., Zhao W., Ono K., Rosensweig C., Chen L., Humala N., Teplow D. B., Pasinetti G. M., Grape-derived polyphenolics prevent A β oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. Journal of Neuroscience 2008 28 25 6388 6392 10.1523/JNEUROSCI.0364-08.2008 2-s2.0-46749123053
33. Jeon B. T., Jeong E. A., Shin H. J., Lee Y., Lee D. H., Kim H. J., Kang S. S., Cho G. J., Choi W. S., Roh G. S., Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 2012 61 6 1444 1454 10.2337/db11-1498 2-s2.0-84861846116
34. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 α Cell 2006 127 6 1109 1122 10.1016/j.cell.2006.11.013 2-s2.0-33845399894
35. Dasgupta B., Milbrandt J., Resveratrol stimulates AMP kinase activity in neurons. Proceedings of the National Academy of Sciences of the United States of America 2007 104 17 7217 7222 10.1073/pnas.0610068104 2-s2.0-34249846128
36. Sharma M., Gupta Y. K., Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sciences 2002 71 21 2489 2498 10.1016/S0024-3205(02)02083-0 2-s2.0-0037063709
37. Kumar A., Naidu P. S., Seghal N., Padi S. S. V., Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology 2007 79 1 17 26 10.1159/000097511 2-s2.0-33845917602
38. Schmatz R., Mazzanti C. M., Spanevello R., Stefanello N., Gutierres J., Corrêa M., da Rosa M. M., Rubin M. A., Chitolina Schetinger M. R., Morsch V. M., Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. European Journal of Pharmacology 2009 610 1-3 42 48 10.1016/j.ejphar.2009.03.032 2-s2.0-65049090141
39. Rahvar M., Nikseresht M., Shafiee S. M., Naghibalhossaini F., Rasti M., Panjehshahin M. R., Owji A. A., Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain. Neurochemical Research 2011 36 5 761 765 10.1007/s11064-010-0396-8 2-s2.0-79954443455
40. Kim D., Nguyen M. D., Dobbin M. M., SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. The EMBO Journal 2007 26 13 3169 3179 10.1038/sj.emboj.7601758 2-s2.0-34447308268
41. Lee E. O., Park H. J., Kang J. L., Kim H.-S., Chong Y. H., Resveratrol reduces glutamate-mediated monocyte chemotactic protein-1 expression via inhibition of extracellular signal-regulated kinase 1/2 pathway in rat hippocampal slice cultures. Journal of Neurochemistry 2010 112 6 1477 1487 10.1111/j.1471-4159.2009.06564.x 2-s2.0-77349084145
42. Ju Y. B., Soon O. C., Choi S.-H., Hyun S. J., Ju Y. K., Bae K., Song K.-S., Yeon H. S., Neuroprotective effect of Smilacis chinae rhizome on NMDA-induced neurotoxicity in vitro and focal cerebral ischemia in vivo. Journal of Pharmacological Sciences 2008 106 1 68 77 10.1254/jphs.FP0071206 2-s2.0-38549170318
43. Han Y. S., Zheng W. H., Bastianetto S., Chabot J. G., Quirion R., Neuroprotective effects of resveratrol against β -amyloid-induced neurotoxicity in rat hippocampal neurons: Involvement of protein kinase C. British Journal of Pharmacology 2004 141 6 997 1005 10.1038/sj.bjp.0705688 2-s2.0-1942472491
44. Bastianetto S., Zheng W.-H., Quirion R., Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. British Journal of Pharmacology 2000 131 4 711 720 10.1038/sj.bjp.0703626 2-s2.0-0035235476
45. Candelario-Jalil E., de Oliveira A. C. P., Gräf S., Bhatia H. S., Hüll M., Muñoz E., Fiebich B. L., Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. Journal of Neuroinflammation 2007 4, article 25 10.1186/1742-2094-4-25 2-s2.0-36849092504
46. Kim Y. A., Lim S.-Y., Rhee S.-H., Park K. Y., Kim C.-H., Choi B. T., Lee S. J., Park Y.-M., Choi Y. H., Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β -amyloid-treated C6 glioma cells. International Journal of Molecular Medicine 2006 17 6 1069 1075 2-s2.0-33745727518
47. Jang J.-H., Surh Y.-J., Protective effect of resveratrol on β -amyloid-induced oxidative PC12 cell death. Free Radical Biology and Medicine 2003 34 8 1100 1110 10.1016/S0891-5849(03)00062-5 2-s2.0-0037446328
48. Ladiwala A. R., Lin J. C., Bale S. S., Marcelino-Cruz A. M., Bhattacharya M., Dordick J. S., Tessier P. M., Resveratrol selectively remodels soluble oligomers and fibrils of amyloid A β into off-pathway conformers. Journal of Biological Chemistry 2010 285 31 24228 24237 10.1074/jbc.M110.133108 2-s2.0-77954907699
49. Kwon K. J., Kim H.-J., Shin C. Y., Han S.-H., Melatonin potentiates the neuroprotective properties of resveratrol against beta-amyloid-induced neurodegeneration by modulating AMP-activated protein Kinase pathways. Journal of Clinical Neurology 2010 6 3 127 137 10.3988/jcn.2010.6.3.127 2-s2.0-78651509603
50. Marambaud P., Zhao H., Davies P., Resveratrol promotes clearance of Alzheimer's disease amyloid- β peptides. The Journal of Biological Chemistry 2005 280 45 37377 37382 10.1074/jbc.M508246200 2-s2.0-27844497059
51. Spanier G., Xu H., Xia N., Tobias S., Deng S., Wojnowski L., Forstermann U., Li H., Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). Journal of Physiology and Pharmacology 2009 60 111 116 2-s2.0-77950469163
52. Feng Y., Wang X. P., Yang S. G., Wang Y. J., Zhang X., Du X. T., Sun X. X., Zhao M., Huang L., Liu R. T., Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology 2009 30 6 986 995 10.1016/j.neuro.2009.08.013 2-s2.0-71249124418
53. Wendeburg L., de Oliveira A. C. P., Bhatia H. S., Candelario-Jalil E., Fiebich B. L., Resveratrol inhibits prostaglandin formation in IL-1 β -stimulated SK-N-SH neuronal cells. Journal of Neuroinflammation 2009 6, article 26 10.1186/1742-2094-6-26 2-s2.0-70449457232
54. Albani D., Polito L., Batelli S., De Mauro S., Fracasso C., Martelli G., Colombo L., Manzoni C., Salmona M., Caccia S., Negro A., Forloni G., The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by α -synuclein or amyloid- β (1-42) peptide. Journal of Neurochemistry 2009 110 5 1445 1456 10.1111/j.1471-4159.2009.06228.x 2-s2.0-68949206606
55. Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J. E., Janle E. M., Lobo J., Ferruzzi M. G., Davies P., Marambaud P., AMP-activated protein kinase signaling activation by resveratrol modulates amyloid- β peptide metabolism. The Journal of Biological Chemistry 2010 285 12 9100 9113 10.1074/jbc.M109.060061 2-s2.0-77950575506
56. Bonda D. J., Lee H.-G., Camins A., Pallàs M., Casadesus G., Smith M. A., Zhu X., The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. The Lancet Neurology 2011 10 3 275 279 10.1016/S1474-4422(11)70013-8 2-s2.0-79951686964
57. Beher D., Wu J., Cumine S., Kim K. W., Lu S.-C., Atangan L., Wang M., Resveratrol is not a direct activator of sirt1 enzyme activity. Chemical Biology and Drug Design 2009 74 6 619 624 10.1111/j.1747-0285.2009.00901.x 2-s2.0-70350524083
58. Zhang F., Liu J., Shi J.-S., Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. European Journal of Pharmacology 2010 636 1-3 1 7 10.1016/j.ejphar.2010.03.043 2-s2.0-77952674793
59. Kumar P., Padi S. S. V., Naidu P. S., Kumar A., Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behavioural Pharmacology 2006 17 5-6 485 492 10.1097/00008877-200609000-00014 2-s2.0-33748310632
60. Ge J.-F., Qiao J.-P., Qi C.-C., Wang C.-W., Zhou J.-N., The binding of resveratrol to monomer and fibril amyloid beta. Neurochemistry International 2012 61 7 1192 1201 10.1016/j.neuint.2012.08.012 2-s2.0-84870057502
61. Ferretta A., Gaballo A., Tanzarella P., Piccoli C., Capitanio N., Nico B., Annese T., Di Paola M., Dell'Aquila C., De Mari M., Ferranini E., Bonifati V., Pacelli C., Cocco T., Effect of resveratrol on mitochondrial function: Implications in parkin-associated familiar Parkinson's disease. Biochimica et Biophysica Acta: Molecular Basis of Disease 2014 1842 7 902 915 10.1016/j.bbadis.2014.02.010 2-s2.0-84897429184
62. Lin T.-K., Chen S.-D., Chuang Y.-C., Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy. International Journal of Molecular Sciences 2014 15 1 1625 1646 10.3390/ijms15011625 2-s2.0-84896703719
63. Khan M. M., Ahmad A., Ishrat T., Khan M. B., Hoda M. N., Khuwaja G., Raza S. S., Khan A., Javed H., Vaibhav K., Islam F., Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Research 2010 1328 139 151 10.1016/j.brainres.2010.02.031 2-s2.0-77950594327
64. Lofrumento D. D., Nicolardi G., Cianciulli A., Nuccio F. D., Pesa V. L., Carofiglio V., Dragone T., Calvello R., Panaro M. A., Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immunity 2014 20 3 249 260 10.1177/1753425913488429 2-s2.0-84898986648
65. Wu Y., Li X., Zhu J. X., Xie W., Le W., Fan Z., Jankovic J., Pan T., Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. NeuroSignals 2011 19 3 163 174 10.1159/000328516 2-s2.0-80052359850
66. Song L., Chen L., Zhang X., Li J., Le W., Resveratrol ameliorates motor neuron degeneration and improves survival in SOD1 G93A mouse model of amyotrophic lateral sclerosis. BioMed Research International 2014 2014 10 483501 10.1155/2014/483501
67. G93A ALS mice. Neurotherapeutics 2014 11 2 419 432 10.1007/s13311-013-0253-y 2-s2.0-84899134148
68. Wang J., Zhang Y., Tang L., Zhang N., Fan D., Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis. Neuroscience Letters 2011 503 3 250 255 10.1016/j.neulet.2011.08.047 2-s2.0-80053223811
69. Walle T., Bioavailability of resveratrol. Annals of the New York Academy of Sciences 2011 1215 1 9 15 10.1111/j.1749-6632.2010.05842.x 2-s2.0-78851469101
70. Ponzo V., Soldati L., Bo S., Resveratrol: a supplementation for men or for mice? Acta Veterinaria Scandinavica 2014 12 article 158 10.1186/1479-5876-12-158 2-s2.0-84901737557
71. Anekonda T. S., Resveratrol-a boon for treating Alzheimer's disease? Brain Research Reviews 2006 52 2 316 326 10.1016/j.brainresrev.2006.04.004 2-s2.0-33747886389
72. a values of (E)-resveratrol as determined by fluorescence spectroscopy and UV-visible absorption. Journal of Agricultural and Food Chemistry 2008 56 17 7600 7605 10.1021/jf800843e 2-s2.0-52649175432
73. Frozza R. L., Bernardi A., Paese K., Hoppe J. B., Da Silva T., Battastini A. M. O., Pohlmann A. R., Guterres S. S., Salbego C., Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. Journal of Biomedical Nanotechnology 2010 6 6 694 703 10.1166/jbn.2010.1161 2-s2.0-79953020260
74. Amiot M. J., Romier B., Anh Dao T.-M., Fanciullino R., Ciccolini J., Burcelin R., Pechere L., Emond C., Savouret J.-F., Seree E., Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie 2013 95 6 1233 1238 10.1016/j.biochi.2013.01.008 2-s2.0-84877729850
75. Kang S. Y., Lee J. K., Choi O., Kim C. Y., Jang J. H., Hwang B. Y., Hong Y. S., Biosynthesis of methylated resveratrol analogs through the construction of an artificial biosynthetic pathway in E. coli. BMC Biotechnology 2014 14 1, article 67 10.1186/1472-6750-14-67
76. Amri A., Chaumeil J. C., Sfar S., Charrueau C., Administration of resveratrol: what formulation solutions to bioavailability limitations? Journal of Controlled Release 2012 158 2 182 193 10.1016/j.jconrel.2011.09.083 2-s2.0-84858709095
77. Das S., Ng K.-Y., Ho P. C., Formulation and optimization of zinc-pectinate beads for the controlled delivery of resveratrol. AAPS PharmSciTech 2010 11 2 729 742 10.1208/s12249-010-9435-7 2-s2.0-77954818667
78. Das S., Ng K.-Y., Resveratrol-loaded calcium-pectinate beads: effects of formulation parameters on drug release and bead characteristics. Journal of Pharmaceutical Sciences 2010 99 2 840 860 10.1002/jps.21880 2-s2.0-74049161626
79. Peng H., Xiong H., Li J., Xie M., Liu Y., Bai C., Chen L., Vanillin cross-linked chitosan microspheres for controlled release of resveratrol. Food Chemistry 2010 121 1 23 28 10.1016/j.foodchem.2009.11.085 2-s2.0-75749121776
80. Das S., Ng K. Y., Ho P. C., Design of a pectin-based microparticle formulation using zinc ions as the cross-linking agent and glutaraldehyde as the hardening agent for colonic-specific delivery of resveratrol: in vitro and in vivo evaluations. Journal of Drug Targeting 2011 19 6 446 457 10.3109/1061186X.2010.504272 2-s2.0-79958773927
81. Moyano-Mendez J. R., Fabbrocini G., de Stefano D., Mazzella C., Mayol L., Scognamiglio I., Carnuccio R., Ayala F., la Rotonda M. I., de Rosa G., Enhanced antioxidant effect of trans-resveratrol: potential of binary systems with polyethylene glycol and cyclodextrin. Drug Development and Industrial Pharmacy 2014 40 10 1300 1307
82. Kobierski S., Ofori-Kwakye K., Müller R. H., Keck C. M., Resveratrol nanosuspensions for dermal application-production, characterization, and physical stability. Pharmazie 2009 64 11 741 747 10.1691/ph.2009.9097 2-s2.0-75749111422
83. Teskač K., Kristl J., The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. International Journal of Pharmaceutics 2010 390 1 61 69 10.1016/j.ijpharm.2009.10.011 2-s2.0-77951256976
84. Jose S., Anju S. S., Cinu T. A., Aleykutty N. A., Thomas S., Souto E. B., In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. International Journal of Pharmaceutics 2014 474 1-2 6 13 10.1016/j.ijpharm.2014.08.003
85. Bonechi C., Martini S., Ciani L., Lamponi S., Rebmann H., Rossi C., Ristori S., Using liposomes as carriers for polyphenolic compounds: the case of Trans-resveratrol. PLoS ONE 2012 7 8 e41438 10.1371/journal.pone.0041438 2-s2.0-84865176466
86. Pangeni R., Sahni J. K., Ali J., Sharma S., Baboota S., Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opinion on Drug Delivery 2014 11 8 1285 1298 10.1517/17425247.2014.919253
87. Ahmed R. Z., Patil G., Zaheer Z., Nanosponges-a completely new nano-horizon: pharmaceutical applications and recent advances. Drug Development and Industrial Pharmacy 2013 39 9 1263 1272 10.3109/03639045.2012.694610 2-s2.0-84881140852
88. Ansari K. A., Vavia P. R., Trotta F., Cavalli R., Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech 2011 12 1 279 286 10.1208/s12249-011-9584-3 2-s2.0-79954424091
89. Pund S., Thakur R., More U., Joshi A., Lipid based nanoemulsifying resveratrol for improved physicochemical characteristics, in vitro cytotoxicity and in vivo antiangiogenic efficacy. Colloids and Surfaces B: Biointerfaces 2014 120 110 117 10.1016/j.colsurfb.2014.05.016 2-s2.0-84901759449
90. Cottart C.-H., Nivet-Antoine V., Laguillier-Morizot C., Beaudeux J.-L., Resveratrol bioavailability and toxicity in humans. Molecular Nutrition and Food Research 2010 54 1 7 16 10.1002/mnfr.200900437 2-s2.0-74349100733
91. Nunes T., Almeida L., Rocha J.-F., Falcão A., Fernandes-Lopes C., Loureiro A. I., Wright L., Vaz-Da-Silva M., Soares-Da-Silva P., Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. Journal of Clinical Pharmacology 2009 49 12 1477 1482 10.1177/0091270009339191 2-s2.0-71449113221
92. Sessa M., Balestrieri M. L., Ferrari G., Servillo L., Castaldo D., D'Onofrio N., Donsì F., Tsao R., Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. Food Chemistry 2014 147 42 50 10.1016/j.foodchem.2013.09.088 2-s2.0-84885356762
93. Planas J. M., Alfaras I., Colom H., Juan M. E., The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Archives of Biochemistry and Biophysics 2012 527 2 67 73 10.1016/j.abb.2012.06.004 2-s2.0-84867099595
94. Neves A. R., Lúcio M., Martins S., Lima J. L. C., Reis S., Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. International Journal of Nanomedicine 2013 8 177 187 10.2147/IJN.S37840 2-s2.0-84872351206
95. Patel K. R., Scott E., Brown V. A., Gescher A. J., Steward W. P., Brown K., Clinical trials of resveratrol. Annals of the New York Academy of Sciences 2011 1215 1 161 169 10.1111/j.1749-6632.2010.05853.x 2-s2.0-78851472303
96. Kennedy D. O., Wightman E. L., Reay J. L., Lietz G., Okello E. J., Wilde A., Haskell C. F., Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. The American Journal of Clinical Nutrition 2010 91 6 1590 1597 10.3945/ajcn.2009.28641 2-s2.0-77953032816
97. Mecocci P., Polidori M. C., Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochimica et Biophysica Acta-Molecular Basis of Disease 2012 1822 5 631 638 10.1016/j.bbadis.2011.10.006 2-s2.0-84858148877